

Gunnar Folprecht

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6855902/gunnar-folprecht-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124 papers	11,304 citations	37 h-index	106 g-index
130 ext. papers	13,323 ext. citations	6.6 avg, IF	5.45 L-index

#	Paper	IF	Citations
124	Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO Past, present, and future <i>Onkologie</i> , 2022 , 28, 44	0.1	0
123	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer.. <i>Frontiers in Genetics</i> , 2021 , 12, 811291	4.5	0
122	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102301	14.4	3
121	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , e215445	13.4	14
120	Influence of the First Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. <i>Frontiers in Public Health</i> , 2021 , 9, 750479	6	2
119	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With Fusion-Positive Carcinoma Harboring the Solvent-Front Mutation. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
118	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021 , 11, 2780-2795	24.4	24
117	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). <i>Strahlentherapie Und Onkologie</i> , 2021 , 197, 19-26	4.3	8
116	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021 , 26, e414-e424	5.7	1
115	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021 , 124, 721-727	8.7	2
114	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021 , 144, 101-112	7.5	4
113	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021 , 144, 281-290	7.5	1
112	The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	1
111	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). <i>International Journal of Cancer</i> , 2021 ,	7.5	1
110	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2389-2401	3.1	7
109	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
108	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. <i>Oncology Research and Treatment</i> , 2020 , 43, 628-636	2.8	22

107	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 420-435	21.7	110
106	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3212-3222	2.2	148
105	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019 , 145, 2282-2291	7.5	13
104	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet, The</i> , 2019 , 393, 1948-1957	40	675
103	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 602	8.4	5
102	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1153-1161	4	7
101	Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. <i>Cancer Communications</i> , 2019 , 39, 74	9.4	12
100	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3520-3520	2.2	4
99	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4120-4120	2.2	2
98	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 571-571	2.2	1
97	Place of death and chemotherapy use at the end of life in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e23006-e23006	2.2	
96	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15025-e15025	2.2	
95	Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3583-3583	2.2	
94	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. <i>Oncolimmunology</i> , 2018 , 7, e1393133	7.2	11
93	Immunotherapy of Colon Cancer. <i>Oncology Research and Treatment</i> , 2018 , 41, 282-285	2.8	22
92	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 379-383	13.4	64
91	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018 , 24, 4745-4753	12.9	14
90	Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. <i>Annals of Oncology</i> , 2018 , 29, 1793-1799	10.3	13

89	Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 59-59	2.2	3
88	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , 2018 , 4, e173695	13.4	37
87	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-13	3.6	4
86	Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for non-small cell lung cancer: a case report. <i>Journal of Chemotherapy</i> , 2017 , 29, 49-53	2.3	6
85	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. <i>Nature Communications</i> , 2017 , 8, 14093	17.4	47
84	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , 2017 , 28, 824-830	10.3	31
83	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	138
82	Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor. <i>Nuklearmedizin - NuclearMedicine</i> , 2017 , 56, N19-N21	1.8	2
81	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
80	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	269
79	CUP Therapie nach Molekularpathologie oder mit Immuntherapie. <i>Onkologe</i> , 2017 , 23, 1006-1010	0.1	
78	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3515-3515	2.2	3
77	Colorectal Liver Metastases: A Critical Review of State of the Art. <i>Liver Cancer</i> , 2016 , 6, 66-71	9.1	51
76	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016 , 63, 11-24	7.5	63
75	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , 2016 , 2, 643-653	13.4	87
74	Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e29-39	3.8	15
73	Preoperative chemoradiotherapy and the long-term run in curative treatment of locally advanced oesophagogastric junction adenocarcinoma: Update of the POET phase III study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4031-4031	2.2	2
72	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX +/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 553-553	2.2	3

71	Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 647-647	2.2	6
70	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. <i>Oncotarget</i> , 2016 , 7, 44322-44329	3.3	33
69	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. <i>Oncotarget</i> , 2016 , 7, 22140-9	3.3	7
68	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 562-562	2.2	
67	Liver Metastases in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e186-92	7.1	6
66	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016 , 27, 1273-9	10.3	51
65	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 979-89	21.7	432
64	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. <i>British Journal of Cancer</i> , 2015 , 113, 1027-34	8.7	28
63	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3506-3506	2.2	2
62	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3507-3507	2.2	6
61	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3634-TPS3634	2.2	2
60	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcOLOR platform.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 575-575	2.2	4
59	Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 598-598	2.2	2
58	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS789-TPS789	2.2	1
57	Mortality from outpatients chemotherapy (CTx) in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17676-e17676	2.2	
56	Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014 , 50, 1590-601	7.5	47
55	European perspective for effective cancer drug development. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 492-8	19.4	36
54	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 862-73	21.7	190

53	Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2014 , 14, 521	4.8	29
52	Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). <i>Annals of Oncology</i> , 2014 , 25, 1018-25	10.3	166
51	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014 , 25, 2378-2385	10.3	72
50	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3549-3549	2.2	
49	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. <i>Experimental & Translational Stroke Medicine</i> , 2013 , 5, 7		13
48	Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population. <i>BMC Cancer</i> , 2013 , 13, 66	4.8	12
47	Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. <i>European Journal of Cancer</i> , 2013 , 49, 439-48	7.5	48
46	Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). <i>Pharmacogenomics Journal</i> , 2013 , 13, 410-6	3.5	12
45	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. <i>Annals of Oncology</i> , 2013 , 24, 1560-7	10.3	65
44	Chemotherapy in the Metastatic Setting 2013 , 129-139		
43	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology</i> , 2012 , 13, 679-87	21.7	484
42	The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 51-57	1.6	1
41	O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Afibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM). <i>Annals of Oncology</i> , 2012 , 23, iv16	10.3	20
40	Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. <i>British Journal of Cancer</i> , 2012 , 107, 1044-50	8.7	14
39	Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 540-540	2.2	7
38	Neoadjuvant chemotherapy for non-/resectable metastases. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S52-60	7.5	4
37	Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 715-6	3.8	9
36	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , 2011 , 11, 509	4.8	53

35	Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. <i>Clinical Cancer Research</i> , 2011 , 17, 4892-900	12.9	102
34	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2011-9	2.2	1463
33	Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. <i>Cancer Research</i> , 2011 , 71, 5670-7	10.1	294
32	Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?. <i>Cancers</i> , 2011 , 3, 2286-301	6.6	2
31	Bevacizumab for recurrent hemangioendothelioma. <i>Acta Oncologica</i> , 2011 , 50, 153-4	3.2	17
30	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>British Journal of Cancer</i> , 2010 , 102, 500-5	8.7	150
29	EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. <i>Cancer Treatment Reviews</i> , 2010 , 36, 83-90	14.4	50
28	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <i>Lancet Oncology</i> , 2010 , 11, 38-47	21.7	738
27	Cetuximab in metastatic colorectal cancer: Author Reply. <i>Lancet Oncology</i> , 2010 , 11, 314	21.7	
26	Comparison of histopathological and gene expression-based typing of cancer of unknown primary. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010 , 456, 23-9	5.1	16
25	Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. <i>Oncology Research and Treatment</i> , 2009 , 32, 162-6	2.8	9
24	Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. <i>British Journal of Cancer</i> , 2009 , 100, 44-9	8.7	53
23	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 1408-17	59.2	3065
22	Accomplishments in 2008 in the management of curable metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S15-22		11
21	Biologicals for Colorectal Cancer Metastases 2009 , 1-7		
20	Introduction: Advances in treatment of metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2008 , 34 Supl 2, S1-2	14.4	3
19	Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1443-51	2.2	181
18	Carcinoma of Unknown Primary - an Orphan Disease?. <i>Breast Care</i> , 2008 , 3, 164-170	2.4	12

17	Chemotherapy in elderly patients with colorectal cancer. <i>Oncologist</i> , 2008 , 13, 390-402	5.7	82
16	Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 215-23	12.9	23
15	Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. <i>Deutsches A&#x0308;rztblatt International</i> , 2008 , 105, 733-40	2.5	22
14	Intravitreal bevacizumab and blood pressure: does it mean safe enough? <i>Acta Ophthalmologica</i> , 2007 , 85, 573-4; author reply 574-5		2
13	Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 942-50	2.8	36
12	Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. <i>Cancer Treatment and Research</i> , 2007 , 134, 425-40	3.5	29
11	Biomarkers for therapeutic efficacy. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 129-142	1.6	4
10	Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 268-76	7.4	57
9	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 450-6	10.3	185
8	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. <i>Annals of Oncology</i> , 2005 , 16, 1311-9	10.3	462
7	Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 578-87		7
6	Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. <i>Annals of Oncology</i> , 2004 , 15, 1330-8	10.3	193
5	The role of new agents in the treatment of colorectal cancer. <i>Oncology</i> , 2004 , 66, 1-17	3.6	33
4	Role of new agents in the treatment of colorectal cancer. <i>Surgical Oncology</i> , 2004 , 13, 75-81	2.5	6
3	Aldosterone activates the nuclear pore transporter in cultured kidney cells imaged with atomic force microscopy. <i>Pflügers Archiv European Journal of Physiology</i> , 1996 , 432, 831-8	4.6	14
2	Immunolocalization of lamins and nuclear pore complex proteins by atomic force microscopy. <i>Pflügers Archiv European Journal of Physiology</i> , 1995 , 430, 795-801	4.6	23
1	Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. <i>Pflügers Archiv European Journal of Physiology</i> , 1995 , 430, 802-7	4.6	44